Renal Care Outlook: Protein-Enriched Dialysis Fluids for Malnourished ESRD Patients
公開 2026/04/02 17:17
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report "Amino Acid-based Peritoneal Dialysis Solution - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Amino Acid-based Peritoneal Dialysis Solution market, including market size, share, demand, industry development status, and forecasts for the next few years.
For nephrologists, dialysis center managers, and healthcare providers treating end-stage renal disease (ESRD) patients, managing both fluid/waste removal and nutritional status is a dual challenge—particularly for malnourished patients undergoing peritoneal dialysis. The global Amino Acid-based Peritoneal Dialysis Solution market addresses this need through a specialized formulation that uses amino acid solutions to provide additional protein and nutritional support during dialysis. Using the peritoneum as a semipermeable membrane, this solution not only removes excess fluid and metabolic waste but also helps improve the patient's nutritional status. It is particularly suitable for peritoneal dialysis patients who are malnourished or require amino acid supplementation.
The global market for Amino Acid-based Peritoneal Dialysis Solution was estimated to be worth US$ 106 million in 2025 and is projected to reach US$ 160 million, growing at a CAGR of 6.1% from 2026 to 2032. In 2024, global sales volume is estimated at 9.58 million units, with an average price of USD 10.5 per unit. This steady growth reflects the increasing prevalence of chronic kidney disease and the recognition of nutritional management as a key component of dialysis care.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097333/amino-acid-based-peritoneal-dialysis-solution
Dual-Function Dialysis for Waste Removal & Nutritional Support
Amino acid-based peritoneal dialysis solution is a specialized formulation used in peritoneal dialysis, primarily composed of amino acid solutions that provide additional protein and nutritional support for patients with chronic renal failure. Using the peritoneum as a semipermeable membrane, this solution not only removes excess fluid and metabolic waste from the body but also helps improve the patient's nutritional status. It is particularly suitable for peritoneal dialysis patients who are malnourished or require amino acid supplementation.
Traditional glucose-based dialysis solutions remove waste and fluid but do not address protein loss during dialysis (patients lose approximately 5-10 grams of amino acids per day). Amino acid-based solutions replace lost proteins while providing metabolic waste removal. Clinical studies have shown improved serum albumin levels and nutritional status in patients using amino acid-based solutions compared to standard glucose solutions.
Industry Segmentation: Volume Sizes & Applications
The Amino Acid-based Peritoneal Dialysis Solution market is segmented by bag volume and healthcare facility type:
2 L: Standard volume for single dialysis exchange, suitable for most adult patients. A large dialysis center reported that 2L bags comprise over 80% of its amino acid solution usage.
2.5 L: Larger volume for patients requiring higher ultrafiltration or larger body habitus.
Others: Custom volumes for pediatric or specialty applications.
Application Segments
Hospital: Inpatient peritoneal dialysis for acute kidney injury or initiation of chronic PD. Hospital settings require immediate availability of multiple formulations.
Clinic: Outpatient dialysis clinics serving chronic PD patients, including routine exchanges and training facilities.
Dialysis Center: Specialized freestanding dialysis centers managing large PD patient populations.
Technology Developments & Market Trends
Over the past six months, several developments have shaped the market. Improved formulation stability has extended shelf life and reduced cold chain requirements for distribution. Dual-chamber bag designs separate amino acids from glucose during storage, improving stability and reducing Maillard reaction byproducts. Patient-friendly bag designs with ergonomic handles and improved connectors have enhanced usability for home dialysis.
The trend toward home-based peritoneal dialysis has accelerated post-pandemic, driving demand for user-friendly solution packaging. Clinical guidelines increasingly recommend nutritional assessment and amino acid supplementation for malnourished PD patients. Reimbursement policies in major markets have expanded coverage for amino acid-based solutions as a medical necessity rather than a premium option.
Regional Market Dynamics
North America leads the amino acid-based peritoneal dialysis solution market, driven by high ESRD prevalence, established home dialysis infrastructure, and favorable reimbursement. The United States dominates with a large PD patient population and Medicare coverage.
Europe follows closely, with strong adoption in Germany, France, and the UK, supported by clinical guidelines recognizing nutritional management in dialysis. Asia-Pacific is the fastest-growing region, with rising ESRD incidence, expanding dialysis access, and growing home PD adoption in China, Japan, and India.
Competitive Landscape
Key players include Baxter, Fresenius, B. Braun, WEGO, Huaren Pharmaceutical, CR Double-Crane, and Qingshan Likang.
Market Segmentation
The Amino Acid-based Peritoneal Dialysis Solution market is segmented as below:
By Company
Baxter
Fresenius
B. Braun
WEGO
Huaren Pharmaceutical
CR Double-Crane
Qingshan Likang
Segment by Volume
2 L
2.5 L
Others
Segment by Application
Hospital
Clinic
Dialysis Center
Exclusive Industry Outlook
Looking ahead, the convergence of amino acid-based dialysis solution technology with personalized nutrition and home dialysis expansion represents a steady growth opportunity. Development of formulations with optimized amino acid profiles for specific patient populations (e.g., diabetic nephropathy, elderly) may improve outcomes. Integration with remote patient monitoring and automated PD cyclers will support home-based care. Additionally, the expansion of PD-first policies in emerging markets will drive demand for specialized solutions. The ability to offer amino acid-based peritoneal dialysis solutions that combine clinical efficacy, patient tolerance, and ease of use—supported by reliable supply chains and regulatory compliance—will define competitive differentiation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
For nephrologists, dialysis center managers, and healthcare providers treating end-stage renal disease (ESRD) patients, managing both fluid/waste removal and nutritional status is a dual challenge—particularly for malnourished patients undergoing peritoneal dialysis. The global Amino Acid-based Peritoneal Dialysis Solution market addresses this need through a specialized formulation that uses amino acid solutions to provide additional protein and nutritional support during dialysis. Using the peritoneum as a semipermeable membrane, this solution not only removes excess fluid and metabolic waste but also helps improve the patient's nutritional status. It is particularly suitable for peritoneal dialysis patients who are malnourished or require amino acid supplementation.
The global market for Amino Acid-based Peritoneal Dialysis Solution was estimated to be worth US$ 106 million in 2025 and is projected to reach US$ 160 million, growing at a CAGR of 6.1% from 2026 to 2032. In 2024, global sales volume is estimated at 9.58 million units, with an average price of USD 10.5 per unit. This steady growth reflects the increasing prevalence of chronic kidney disease and the recognition of nutritional management as a key component of dialysis care.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097333/amino-acid-based-peritoneal-dialysis-solution
Dual-Function Dialysis for Waste Removal & Nutritional Support
Amino acid-based peritoneal dialysis solution is a specialized formulation used in peritoneal dialysis, primarily composed of amino acid solutions that provide additional protein and nutritional support for patients with chronic renal failure. Using the peritoneum as a semipermeable membrane, this solution not only removes excess fluid and metabolic waste from the body but also helps improve the patient's nutritional status. It is particularly suitable for peritoneal dialysis patients who are malnourished or require amino acid supplementation.
Traditional glucose-based dialysis solutions remove waste and fluid but do not address protein loss during dialysis (patients lose approximately 5-10 grams of amino acids per day). Amino acid-based solutions replace lost proteins while providing metabolic waste removal. Clinical studies have shown improved serum albumin levels and nutritional status in patients using amino acid-based solutions compared to standard glucose solutions.
Industry Segmentation: Volume Sizes & Applications
The Amino Acid-based Peritoneal Dialysis Solution market is segmented by bag volume and healthcare facility type:
2 L: Standard volume for single dialysis exchange, suitable for most adult patients. A large dialysis center reported that 2L bags comprise over 80% of its amino acid solution usage.
2.5 L: Larger volume for patients requiring higher ultrafiltration or larger body habitus.
Others: Custom volumes for pediatric or specialty applications.
Application Segments
Hospital: Inpatient peritoneal dialysis for acute kidney injury or initiation of chronic PD. Hospital settings require immediate availability of multiple formulations.
Clinic: Outpatient dialysis clinics serving chronic PD patients, including routine exchanges and training facilities.
Dialysis Center: Specialized freestanding dialysis centers managing large PD patient populations.
Technology Developments & Market Trends
Over the past six months, several developments have shaped the market. Improved formulation stability has extended shelf life and reduced cold chain requirements for distribution. Dual-chamber bag designs separate amino acids from glucose during storage, improving stability and reducing Maillard reaction byproducts. Patient-friendly bag designs with ergonomic handles and improved connectors have enhanced usability for home dialysis.
The trend toward home-based peritoneal dialysis has accelerated post-pandemic, driving demand for user-friendly solution packaging. Clinical guidelines increasingly recommend nutritional assessment and amino acid supplementation for malnourished PD patients. Reimbursement policies in major markets have expanded coverage for amino acid-based solutions as a medical necessity rather than a premium option.
Regional Market Dynamics
North America leads the amino acid-based peritoneal dialysis solution market, driven by high ESRD prevalence, established home dialysis infrastructure, and favorable reimbursement. The United States dominates with a large PD patient population and Medicare coverage.
Europe follows closely, with strong adoption in Germany, France, and the UK, supported by clinical guidelines recognizing nutritional management in dialysis. Asia-Pacific is the fastest-growing region, with rising ESRD incidence, expanding dialysis access, and growing home PD adoption in China, Japan, and India.
Competitive Landscape
Key players include Baxter, Fresenius, B. Braun, WEGO, Huaren Pharmaceutical, CR Double-Crane, and Qingshan Likang.
Market Segmentation
The Amino Acid-based Peritoneal Dialysis Solution market is segmented as below:
By Company
Baxter
Fresenius
B. Braun
WEGO
Huaren Pharmaceutical
CR Double-Crane
Qingshan Likang
Segment by Volume
2 L
2.5 L
Others
Segment by Application
Hospital
Clinic
Dialysis Center
Exclusive Industry Outlook
Looking ahead, the convergence of amino acid-based dialysis solution technology with personalized nutrition and home dialysis expansion represents a steady growth opportunity. Development of formulations with optimized amino acid profiles for specific patient populations (e.g., diabetic nephropathy, elderly) may improve outcomes. Integration with remote patient monitoring and automated PD cyclers will support home-based care. Additionally, the expansion of PD-first policies in emerging markets will drive demand for specialized solutions. The ability to offer amino acid-based peritoneal dialysis solutions that combine clinical efficacy, patient tolerance, and ease of use—supported by reliable supply chains and regulatory compliance—will define competitive differentiation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ